中国人群糖尿病足相关危险因素的Meta分析

doi:10.3969/j.issn.1673-8640.2014.06.015

摘要/Abstract

摘要： 目的通过Meta分析探讨中国人群糖尿病足相关危险因素。方法计算机检索中国期刊全文数据库(CNKI)、维普中文科技期刊全文数据库(VIP)、Pubmed、EMbase、中国生物医学文献检索数据库(CBM)和万方科技期刊全文数据库等数据库,并手工检索相关文献,检索关于中国人群糖尿病足相关危险因素的病例-对照研究,检索时限均从建库至2013年12月。由两名评价者根据纳入、排除标准独立选择文献、提取资料、评价质量后采用RevMan5.0软件进行Meta分析,用固定效应模型或随机效应模型合并比值比(OR)值及95%可信区间(CI)分析各个相关危险因素,采用敏感性分析评估结果的稳定性,用漏斗图评估文献的发表偏倚。结果共纳入15篇文献,Meta分析结果显示影响糖尿病足发生的重要危险因素有年龄(OR＝7.51,95%CI:6.74～8.28)、病程(OR＝3.34,95%CI:2.96～3.72)、体重指数(BMI)(OR＝-0.53,95%CI:－0.80～－0.26)、收缩压(OR＝9.84,95%CI:8.08～11.60)、舒张压(OR＝1.03,95%CI:0.03～2.03)、空腹血糖(FPG)(OR＝1.48,95%CI:1.19～1.77)、餐后2 h血糖(2 hPG)(OR＝2.15,95%CI:1.71～2.59)、糖化血红蛋白(HbA_1c)(OR＝1.46,95%CI:1.03～1.88)、血清总胆固醇(TC)(OR＝－0.31,95%CI:－0.42～－0.19)、高密度脂蛋白胆固醇(HDL-C)(OR＝－0.07,95%CI:－0.10～－0.03),差异均有统计学意义(P<0.01);而甘油三酯(TG)(OR＝－0.06,95%CI:－0.16～0.04)和低密度脂蛋白胆固醇(LDL-C)(OR＝－0.05,95%CI:－0.21～0.11)对糖尿病足的发病与否无明显影响(P>0.05)。结论初步确定年龄、病程、BMI、收缩压、舒张压、FPG、2 hPG、HbA_1c、TC、HDL-C是影响糖尿病足发生的重要危险因素,为临床上糖尿病足发生的早期防预提供依据。

关键词: 糖尿病足, 危险因素, Meta分析

Abstract: Objective To use Meta analysis to evaluate the risk factors of diabetic foot in China. Methods The following databases such as China National Knowledge Infrastructure (CNKI), Chinese Weipu Database, Pubmed,EMbase, Chinese Biological Medicine Database(CBM),WANFANG Database and handsearched relevant literature were searched to collect case-control studies on the related risk factors of diabetic foot in China.The retrieval time reached from inception to December, 2013. Two reviewers independently screened the literature according to the inclusion and exclusion criteria, extracted the data and assessed the quality.The Meta analysis was performed by RevMan5.0 software. The various risk factors were analyzed by fixed effect model or random effect model pooled odds ratio(OR)and 95% confidence interval (CI), with stability evaluated by sensitivity analysis.Moreover, the funnel plot was used to assess the published bias of articles. Results A total of 15 articles were included, the key risk factors such as age(OR=7.51, 95%CI: 6.74-8.28), course of disease(OR=3.34, 95%CI: 2.96-3.72), body mass index(BMI)(OR=-0.53, 95%CI:-0.80-0.26), systolic blood pressure(OR=9.84, 95%CI: 8.08-11.60), diastolic blood pressure(OR=1.03, 95%CI: 0.03-2.03), fasting blood glucose(FPG)(OR=1.48, 95%CI: 1.19-1.77), 2 h post prandial blood glucose(2 hPG)(OR=2.15, 95% CI: 1.71-2.59), glycosylated hemoglobin A_1c(HbA_1c)(OR=1.46, 95%CI: 1.03-1.88), total cholesterol(TC)(OR=-0.31, 95%CI: -0.42-0.19) and high-density lipoprotein-cholesterol(HDL-C)(OR=-0.07, 95%CI: -0.10-0.03) (P<0.01)affected the happening of diabetic foot, but triglyceride (TG) (OR=-0.06, 95%CI: -0.16-0.04), low-density lipoprotein-cholesterol(LDL-C)(OR=-0.05, 95%CI: -0.21-0.11)did not statistically influence on diabetic foot(P>0.05). Conclusions Age, course of disease, BMI, systolic blood pressure, diastolic blood pressure, FPG, 2 hPG, HbA_1c, TC and HDL-C are primarily determined as the important risk factors of diabetic foot, which can provide the reference for the early prevention of diabetic foot occurred in clinic.

Key words: Diabetic foot, Risk factor, Meta analysis

中图分类号:

Q587.2

赵静静,王伟灵,郑培莉. 中国人群糖尿病足相关危险因素的Meta分析[J]. 检验医学, 2014, 29(6): 640-645.

ZHAO Jingjing,WANG Weiling,ZHENG Peili. Risk factors of diabetic foot in China: a Meta analysis[J]. , 2014, 29(6): 640-645.

参考文献

[1] Fard AS,Esmaelzadeh M,Larijjani B. Assessment and treatment of diabetic foot ulcer [J] . Int J Clin Pract,2007,61(11):1931-1938.
[2] 张喜英,王涤非.2型糖尿病患者糖尿病足危险因素研究[J] .中国全科医学,2011,14(15):1629-1631.
[3] Andrew B.The diabetic foot:epidemiology, risk factors and the status of care[J] .Diabetes Voice,2005,50(Special issue):5-7.
[4] Boulton AJ.The diabetic foot: grand overview, epidemiology and pathogenesis[J] .Diabeties Metab Res Rev,2008,24(Suppl 1):S3-S6.
[5] Public Health Resource Unit, England. Critical Appraisal Skills Programme(CASP),11 questions to help you make sense of a case control study.Case control questions [EB/OL] .(2010-07-26) [2012-07-03] . http://www.sph.nhs.uk/search? Searchable Text=Case+Control+Questions&x=19&y=6.
[6] 代雪梅,沈霞蔚,肖醉萱.2型糖尿病患者糖尿病足发病的相关因素分析[J] .疑难病杂志,2013,12(4):310-311.
[7] 伍军伟,凌俊宏,王福诩,等.糖尿病足的危险因素分析[J] .中国临床新医学,2009,2(6):611-614.
[8] 刘树文,李宝纯,杨金玲.促进糖尿病足发生的危险因素分析[J] .中国误诊学杂志,2008,18(22):5317-5318.
[9] 夏雪蓓,李茂荣,康宇. 糖尿病足危险因素探讨[J] .实用糖尿病杂志,2000,2(2):28-30.
[10] 姜春艳,刘艳.糖尿病足危险因素分析[J] .临床荟萃,2010,25(4):336-338.
[11] 常宝成,曾淑范. 第六次全国中西医结合糖尿病学术会议论文汇编[C] .黄山:中国中西医结合学会糖尿病专业委员会,2002:378-381.
[12] 张艳,袁迎春,李小风.糖尿病足64例相关危险因素分析及护理[J] .齐鲁护理杂志,2011,17(1):62-64.
[13] 李娜,肖珊,朱筠.2型糖尿病患者糖尿病足的相关危险因素分析[J] .新疆医科大学学报,2009,32(1):26-28.
[14] 李蓉.2型糖尿病患者糖尿病足的危险因素分析研究[J] .实用预防医学,2009,16(6):1950-1951.
[15] 林揆斌,沈阳.2型糖尿病患者糖尿病足的危险因素分析[J] .热带医学杂志,2011,11(8):941-943.
[16] 沈艳军,毕会民.糖尿病足发生发展的危险因素[J] .中国老年学杂志,2012,32(6):1153-1156.
[17] 谢小娥,陈小娟,黄燕芳,等.糖尿病足危险因素分析及预防[J] .按摩与康复医学(下旬刊),2012,3(1):16-17.
[18] 邓利娟.2型糖尿病患者发生糖尿病足高危因素的临床分析[J] .临床内科杂志,2012,27(4):272-273.
[19] 邱伟,梁维娟,宋瑞芳.2型糖尿病患者糖尿病足相关危因素研究[J] .中原医刊,2006,35(10):12-13.
[20] 黄红艳.2型糖尿病合并DF患者的危险因素分析[J] .山东医药,2007,47(25):68-69.
[21] 中华医学会糖尿病分会糖尿病慢性并发症调查组.全国住院糖尿病患者慢性并发症及其相关危险因素10年回顾性调查分析[J] .中国糖尿病杂志,2003,11(4):232-237.
[22] 马晓静,胡承,周健,等.2型糖尿病家系一级亲人群代谢综合征患病情况及与肥胖相关指标的关系[J] .中华内分泌代谢杂志,2009,25(3):286-290.
[23] 甘小玲,陈庆瑜,廖蓓,等.体重指数对血糖、血脂及血压的影响[J] .临床医学,2010,30(6):9-10.
[24] Shen J, Liu F, Zeng H, et al. Vibrating perception threshold and body mass index are associated with abnormal foot plantar pressure in type 2 diabetes outpatients[J] .Diabetes Technol Ther,2012,14(11):1053-1059.
[25] 常宝成,潘从清,曾淑范.208例糖尿病足流行病学及临床特点分析[J] .中华糖尿病杂志,2005,13(2):129-130.
[26] Shahbazian H,Yazdanpanah L,Latifi SM. Risk assessment of patients with diabetes for foot ulcers according to risk classification consensus of International Working Group on Diabetic Foot(IWGDF)[J] .Pak J Med Sci,2013,29(3):730-734.
[27] 陈国良,刘立伟,谢爽,等.高密度脂蛋白胆固醇代谢及其对冠心病影响的研究进展[J] .心血管病学进展,2010,31(3):360-363.
[28] Li X,Xiao T,Wang Y,et al.Incidence,risk factors for ampution among patients with diabetic foot ulcer in a Chinese tertiary hospital[J] .Diabetes Res Clin Pract,2011,93(1):26-30.
[29] Ansquer JC,Foucher C,Aubonnet P,et al.Fibrates and microvascular complications in diabetes--insight from the FIELD study[J] .Curr Pharm Des,2009,15(5):537-552.
[30] Chehade JM,Gladysz M,Mooradian AD.Dyslipidemia in type 2 diabetes:prevalence, pathophysiology,and management[J] . Drugs,2013,73(4):327-339.